

M&G invests in UK-based innovator e-therapeutics

London, 07 November 2022 – M&G Investments has provided a further £13.5 million of funding and an increased shareholding in e-therapeutics, a UK-based innovator in computer technology for the development of life-transforming medicines.

e-therapeutics combines two platform technologies; a computational drug discovery platform and its specialised silenced RNA drugs, which target the liver specifically. The combination of these technologies shortens the time and cost it takes a drug from target discovery to market, which currently takes on average, around 10 years.

The additional funding will be used to scale up e-therapeutics' operations and facilitate further growth, including enhancing its proprietary drug discovery and development platform capabilities. The investment is being facilitated through the issuance of Subscription Shares, increasing M&G's holding in the company to 17.5%, signalling its long term commitment to supporting e-therapeutics' aims and ambitions.

Michael Stiasny, Head of UK Equities at M&G Investments says: "With the potential to re-shape the conventional drug discovery model, we believe e-therapeutics' unique platform and AI capabilities has the potential to increase the speed in which highly-specific drugs can be developed for patients, while increasing efficiency and reducing the costs associated with in-vitro trials. This investment demonstrates the crucial role patient capital can play in supporting the next generation of medical research."

Ali Mortazavi, Chief Executive Officer of e-therapeutics says: "We are pleased to have continued our long-standing relationship with M&G, and this refinancing is an important step in us extending our cash runway and ability to prosecute our computationally derived drug targets."

-ENDS-

Notes to Editors

If you require any further information, please contact:

M&G Investments – Eoghan Hughes

Corporate Communications
eoghan.hughes@mandg.co.uk
+44 (0)7852 881 983

About e-therapeutics

e-therapeutics plc (AIM: ETX; OTCQX; ETXPF) is a UK-based company integrating computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture

and model human biology, identify novel targets and design RNAi medicines against those targets that can be rapidly progressed to the clinic.

ETX's proprietary Computational Biology Platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery that explicitly considers the true complexity of biology and makes more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledge base, - the world's most comprehensive and integrated hepatocyte-centric data and information resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by ETX's Computational Biology Platform. The focus on hepatocytes offers the opportunity to work across a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates in several therapeutic areas including haematology, cardiovascular disease and non-alcoholic steatohepatitis ("NASH"). ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

About M&G Investments

M&G Investments is part of M&G plc, a savings and investment business which was formed in 2017 through the merger of Prudential plc's UK and Europe savings and insurance operation and M&G, its wholly owned international investment manager. M&G plc listed as an independent company on the London Stock Exchange in October 2019 and has over £348 billion of assets under management (as at 30 June 2022). M&G plc has customers in the UK, Europe, the Americas and Asia, including individual savers and investors, life insurance policy holders and pension scheme members.

For nearly nine decades M&G Investments has been helping its customers to prosper by putting investments to work, which in turn creates jobs, homes and vital infrastructure in the real economy. Its investment solutions span equities, fixed income, multi asset, cash, private debt, infrastructure and real estate.

M&G recognises the importance of responsible investing and is a signatory to the United Nations Principles for Responsible Investment (UNPRI) and is a member of the Climate Bonds Initiative Partners Programme.

M&G plc has committed to achieve net zero carbon emissions on its total book of assets under management and administration by 2050 and committed to reduce operational carbon emissions as a corporate entity to net zero by 2030.

For more information, please visit: <https://global.mandg.com/>

This information is intended for journalists and media professionals only. It should not be relied on by private investors or advisers. Please note that not all of the funds referenced in this press release will be available in your jurisdiction.

Issued by M&G Securities Limited which is authorised and regulated by the Financial Conduct Authority and provides investment products. The company's registered office is 10 Fenchurch Avenue, London EC3M 5AG. Registered in England and Wales. Registered number 90776.